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Objective: Angiopoietin-2 (Ang-2) blocking agents are currently undergoing clinical trials for use in
cancer treatment. Ang-2 has also been associated with rupture-prone atherosclerotic plaques in humans,
suggesting a role for Ang-2 in plaque stability. Despite the availability of Ang-2 blocking agents, their
clinical use is still lacking. Our aim was to establish if Ang-2 has a role in atheroma development and in
the transition of subclinical to clinically relevant atherosclerosis. We investigated the effect of antibody-
mediated Ang-2 blockage on atherogenesis after in a mouse model of atherosclerosis.
Methods: Hypercholesterolemic (low-density lipoprotein receptor/ apolipoprotein B100/100) mice were
subjected to high-cholesterol diet for eight weeks, one group with and one group without Ang-2
blocking antibody treatment during weeks 4e8.To enhance plaque development, a peri-adventitial
collar was placed around the carotid arteries at the start of antibody treatment. Aortic root, carotid ar-
teries and brachiocephalic arteries were analyzed to evaluate the effect of Ang-2 blockage on athero-
sclerotic plaque size and stable plaque characteristics.
Results: Anti-Ang-2 treatment reduced the size of fatty streaks in the brachiocephalic artery (72%,
p < 0.05). In addition, antibody-mediated Ang-2 blockage reduced plasma triglycerides (27%, p < 0.05).
In contrast, Ang-2 blockage did not have any effect on the size or composition (collagen content,
macrophage percentage, adventitial microvessel density) of pre-existing plaques in the aortic root or
collar-induced plaques in the carotid artery.
Conclusions: Ang-2 blockage was beneﬁcial as it decreased fatty streak formation and plasma triglyceride
levels, but had no adverse effect on pre-existing atherosclerosis in hypercholesterolemic mice.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).giopoietin-2; ApoB, apolipo-
P, matrix metalloproteinase;
nd, A.I. Virtanen Institute for
Molecular Medicine, P.O. Box
erttuala).
Ireland Ltd. This is an open access1. Introduction
Increased plasma levels of the vascular growth factor
angiopoietin-2 (Ang-2) occur in several diseases, including cancer
[1], systemic infections [2], and in cardiovascular diseases such as
acute myocardial infarction [3]. Ang-2 is also increased in highly
vascularized, rupture-prone human atherosclerotic plaques [4,5].
Despite the detrimental role of Ang-2 in atherosclerosis suggested
by these results, Ang-2 overexpression decreased plaque size in aarticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
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systemic Ang-2 overexpression fails to mimic the function of
endogenous Ang-2 in atherogenesis.
Despite increased Ang-2 levels in clinically relevant athero-
sclerosis and the availability of Ang-2 blocking agents, there have
been no attempts to study Ang-2 blockage in cardiovascular dis-
eases. Therefore, we considered it important to study the role of
Ang-2 blocking as a therapeutic strategy in atherosclerosis. Because
the blocking of vascular endothelial growth factor in cancer therapy
increased the risk of unpredicted cardiovascular side effects, such
as arterial thrombosis, heart failure or cardiomyopathy [7e10], and
because anti-Ang-2 therapy is currently used for cancer treatment
as well, we aimed to evaluate the potential cardiovascular risk of
anti-Ang-2 treatment in an experimental setting of pre-existing
atherosclerosis. In order to investigate the role of endogenous
Ang-2, a blocking strategy was adopted. Currently, a wide variety of
Ang-2 blocking agents are being tested in clinical trials (some of
them in Phase III) against different types of cancer (reviewed in
[11]). We used an antibody that inhibits tumor growth in mice by
blocking Ang-2 binding to its receptor Tie-2 [12].
The therapeutic potential of Ang-2 blockage is based on the
adverse effects of Ang-2 on processes leading to plaque instability:
microvessel growth (angiogenesis), decreased pericyte coating of
microvasculature and increased vascular permeability [2,13,14],
that promotes leukocyte recruitment [13,15,16]. In addition, Tie-2
expressing macrophages respond to Ang-2 by secreting TNFa [17],
which can contribute to the inﬂammation in the vessel wall.
Microvessel growth and permeability, and inﬂammation are
also involved in the transition of a clinically silent, stable athero-
sclerotic plaque into a vulnerable plaque at risk of ﬁbrous cap
rupture and ensuing clinical events [18]. The abundance and
compromised structural integrity of plaque microvessels are
detrimental to plaque stability, increasing the likelihood of plaque
rupture [18e20]. Structurally abnormal microvessels involve the
risk of plaque hemorrhage and lead to increased lipoprotein
deposition and inﬂux of leukocytes, triggering a pro-inﬂammatory
cycle that results in plaque weakening.
In this study, we investigated the effects of the Ang-2 blocking
antibody on fatty streak formation and atherosclerotic plaque
progression in aortic root, brachiocephalic arteries and in collar-
induced carotid atherosclerosis in LDLr/ ApoB100/100 mice.
2. Materials and methods
2.1. Experimental animals
Ten to twelve week old male LDLR/ ApoB100/100 mice (n ¼ 26)
were placed on a high cholesterol diet (42% of calories from fat and
0.15% from cholesterol, no sodium cholate; TD 88173 Harlan Teklad,
Boxmeer, NL) for 8 weeks. After 3 weeks of diet, mice underwent
collar placement surgery as previously described [21]. In brief, the
mice were anaesthetized with isoﬂurane (induction: 4.5% iso-
ﬂurane, 450ml air, maintenance: 2.0% isoﬂurane, 200ml air; Baxter
International, Helsinki, Finland) and injected with 0.1 mg Rimadyl
s.c. (Pﬁzer, Helsinki, FI). Anesthesia was controlled regularly by
visual inspection and toe pinch reﬂex. Carotid arteries were
accessed via a sagittal anterior neck incision and dissected from the
surrounding tissue without damaging the vagus nerve or the ca-
rotid arteries. A 2 mm silastic collar was placed bilaterally, right
under the bifurcation and ﬁxed with three circumferential surgical
silk knots.
One day after collar placement surgery, the mice were distrib-
uted randomly and injected intraperitoneally with either a mono-
clonal Ang-2 blocking antibody [12] (n ¼ 14) or a control
immunoglobulin (n ¼ 12; IgG) at a dose of 10 mg/kg, as previouslydescribed [22]. The injections were repeated three times weekly
over a total time of ﬁve weeks.
Food and water were provided ad libitum during the entire
study. All animal experiments were approved by National Experi-
mental Animal Board of Finland and carried out in accordance with
guidelines of the Finnish Act on Animal Experimentation.
2.2. Plasma Ang-2 levels
Plasma Ang-2 concentrations were measured using enzyme
linked immunosorbent assay for murine Ang-2 (R&D systems,
Abingdon, UK).
2.3. Echocardiography and carotid artery ultrasound
Echocardiographic measurements were performed before the
collar operations and at 5 weeks after the operation/antibody
treatment using the Vevo® 2100 Ultrasound System (VisualSonics®,
Amsterdam, NL). The animals were anesthetized with isoﬂurane.
The Ejection fraction (EF), fractional shortening (FS), left ventricle
(LV) mass, LV diastolic and systolic volume were analyzed from
parasternal short axis M-mode measurements. EF was calculated
by Vevo2100 software using the Teicholz formula [23]. Carotid
strainwasmeasured as percent change in the arterial diameter: (SD
e DD)/DD, where SD was the systolic and DD the diastolic CCA
diameter. Peak wall shear stress at 1 mm proximal to the collar was
calculated by the Poiseuille equation: t (dyn/cm2) ¼ 4  V  h/ID,
where V is the peak systolic ﬂow velocity (cm/s), h is the blood
viscosity (taken as 0.035 P), and ID is the maximal lumen diameter
of the targeted carotid artery (cm) [24,25].
2.4. Total serum cholesterol and triglycerides
Plasma was separated by centrifugation and stored at 80 C
until further use. Cholesterol was determined using standard
enzymatic assays (CHOD-PAP method - Cholesterol FS Ecoline
product no. 1 1300 99 90 314, DiaSys, Holzheim, GE), as were tri-
glyceride levels (GPO method - Triglycerides FS Ecoline REF 1 5760
99 90 314 both DiaSys).
2.5. Atherosclerotic plaque quantiﬁcation and
immunohistochemistry
Atherosclerotic plaque development in the murine arterial tree
starts in the aortic root, extending to the aortic arch and brachio-
cephalic trunk and, after an extended time period, developing into
the carotid bifurcation [26]. In this study, the mice were fed a high
cholesterol diet for 8 weeks and subjected to antibody treatment
during the last 5 weeks. The plaques in the brachiocephalic artery
consisted mainly of foamy macrophages without an overlying cap
or extracellular cholesterol crystals, thus termed fatty streaks. The
plaques in the aortic root and carotid arteries were classiﬁed as
advanced plaques composed of immune cells, smooth muscle cells
and a necrotic core, all covered by a ﬁbrous cap. The antibody effect
on fatty streak formation could thus be studied in the brachioce-
phalic artery, while the effect on progression of pre-existing,
advanced plaques was studied in the aortic root and carotid ar-
teries with a collar placement, respectively.
Mice were euthanized by CO2 asphyxiation and blood was
collected via the right ventricle for ELISA, total cholesterol- and
triglyceride analysis. Remaining blood was cleared by perfusion
with 20ml PBS via the left ventricle. Brachiocephalic arteries, aortic
root and right common carotid arteries were excised and immer-
sion ﬁxed in 1% paraformaldehyde overnight.
Tissue samples were parafﬁn embedded, serially sectioned
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Zwijndrecht, NL) for quantiﬁcation of the plaque areas using
computerized morphometry (Leica QWin V3, Cambridge, UK). Total
plaque area and necrotic core content were obtained by averaging
measurements of ﬁve representative sections of the brachioce-
phalic artery, aortic root and right common carotid artery. The
necrotic core was deﬁned by cholesterol clefts, lipid droplets and
acellular regions. Collagen content was determined from repre-
sentative sections stained with Sirius Red (Sirius Redþ area/plaque
area; Sigma). Plaque macrophages and the intra-plaque and
adventitial microvessels were quantiﬁed using immunohisto-
chemistry for Mac-3 (Mac-3þ area/plaque area; BD Pharmingen,
Breda, NL) and PCAM-1 (BD Pharmingen, Breda, NL) respectively.2.6. Statistical analysis
All data are presented as mean ± SEM. Following ShapiroeWilk
test for normal distribution, the groups were compared with stu-
dent's t-test or ManneWhitney rank-sum test. (GraphPad Prism4,
La Jolla, CA, USA). A p-value of p < 0.05 was considered signiﬁcant.3. Results
3.1. Ang-2 blocking decreases plasma triglycerides but not plasma
cholesterol levels
The Ang2 antibody used in the study blocks the Ang-2 ﬁbrin-
ogen binding domain that is responsible for receptor binding [12],
and this results in increased Ang-2 levels in the circulation [27]. The
antibody injections resulted in an almost 30-fold increased plasma
Ang-2 concentration after ﬁve weeks of treatment (Fig. 1A). An
increase in plasma Ang-2 has also been described in humansFig. 1. Anti Ang-2 antibody treatment increases plasma Ang-2 levels and decreases plasma
weeks of administration, the antibody treatment did not affect the general health status, b
plantation (K þ L). However, the treatment led to a decrease in plasma triglycerides (D) w
**p < 0.01.treated with the anti-Ang-2 antibody [27]. During ﬁve weeks of
administration, the antibody treatment did not affect the general
health status, including body weight (Fig. 1B), cardiac function
(Fig. 1EeJ) or shear stress in carotid artery after collar implantation
(Fig. 1K and L). However, the treatment led to a 27% decrease in
plasma triglycerides (Fig. 1D) without any effects on plasma
cholesterol (Fig. 1C).3.2. Ang-2 blocking decreases fatty streak formation
In order to investigate if Ang-2 blockage affects fatty streak
formation, the brachiocephalic artery [28] was analyzed after eight
weeks of high-cholesterol diet. Interestingly, fatty streak formation
in the brachiocephalic artery was signiﬁcantly less in mice treated
with the anti-Ang-2 antibody than control IgG (Fig. 2AeC). While
anti-Ang-2 therapy reduced the percentage of stenosis, the lumen
and media size remained unchanged (Fig. 2DeF). Furthermore,
Ang-2 blockage did not alter the fatty streak composition: the
collagen content and the percentage of Mac-3 positive macro-
phages in the plaques (Fig. 2GeI and JeL, respectively) remained
unaltered. No microvessels were found in the fatty streaks and
adventitial microvessel density was not altered by the antibody
treatment (Fig. 2MeO and data not shown).3.3. Existing and advanced plaques are not affected by antibody-
mediated Ang-2 blockage
Mice were fed a high-cholesterol diet for three weeks followed
by anti-Ang-2 antibody treatment while the diet was continued.
This allowed us to analyze the pre-existing plaques in the aortic
root in addition to fatty streaks in the brachiocephalic artery. Pla-
que sizes in aortic roots of mice treated with anti-Ang-2 did nottriglycerides. Plasma Ang-2 levels in anti-Ang and IgG treated mice (A). During the ﬁve
ody weight (B), cardiac function (EeJ) or shear stress in carotid artery after collar im-
ithout effects on plasma cholesterol (C). IgG n ¼ 12; anti-Ang-2 n ¼ 14; *p < 0.05;
Fig. 2. Antibody mediated Ang-2 blockage delays fatty streak formation in the brachiocephalic artery. Representative images of HE-stained brachiocephalic arteries (A þ B) show a
decrease in fatty streak size in animals treated with anti Ang-2 antibody (C). There is no difference in lumen area or medial thickness (D þ E) but a reduction in stenosis after anti-
Ang-2 treatment (F). Plaque collagen content (percentage of Sirius Red positive area/total plaque area, GeI), percentage of macrophage area (Mac3þ area/total plaque area, JeL) and
adventitial microvessel density (microvessels/mm2) (MVD) (MeO). Representative images: left panels IgG, right panels anti-Ang-2 antibody. IgG n ¼ 12; anti-Ang-2 n ¼ 14;
*p < 0.05.
T.L. Theelen et al. / Atherosclerosis 241 (2015) 297e304300differ from control IgG injected mice after eight weeks of high-
cholesterol diet and ﬁve weeks of antibody administration
(Fig. 3AeC). In addition, the treatment did not alter the amount of
necrotic core (Fig. 3A, B and D), collagen content (Fig. 3EeG) or the
macrophages in the plaques (Fig. 3HeJ). No changes in intra-plaque
vessels or adventitial microvessel density were observed(Fig. 3KeM and data not shown). Hence, Ang-2 blockage did not
interfere with the progression or stability of pre-existing plaques.
In addition to the pre-existing plaques in the aortic root, we
were interested in the effects of the antibody on collar-induced
fast-growing advanced plaques. The plaque size and necrotic core
content in these rapidly progressing collar-induced advanced
Fig. 3. Anti Ang-2 antibody treatment does not alter pre-existing atherosclerosis in the aortic root. Representative images of HE-stained plaques in the aortic root (A þ B) show no
difference in plaque size (C) or necrotic core (D) in pre-existing plaques of the aortic root after antibody treatment. Also, collagen (percentage of Sirius Red positive area/total plaque,
EeG), macrophage content (Mac3þ area/total plaque area, HeJ) and adventitial microvessel density (microvessels/mm2, KeM) were not altered by the anti-Ang-2 antibody
treatment. Representative pictures: left panels control IgG, right panels anti-Ang-2. IgG n ¼ 12; anti-Ang-2 n ¼ 14.
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treated mice (Fig. 4AeD). The effect of anti-Ang-2 on fatty streak
formation and atherosclerotic plaque development has been sum-
marized in Table 1.4. Discussion
Our study is the ﬁrst one to investigate Ang-2 depletion in
experimental atherosclerosis and the results demonstrate that
antibody-mediated Ang-2 depletion reduces fatty streak formation
in the brachiocephalic arteries. In addition, anti-Ang-2 treatment
reduces plasma triglycerides while plasma cholesterol levels
remain unchanged. The anti-Ang-2 antibody did not interfere with
pre-existing plaques of the aortic root or with collar-induced pla-
ques in the carotid artery. Moreover, Ang-2 depletion had no effect
on the stability of the plaque phenotype as microvessel density,
macrophage and collagen content and the necrotic cores remainedunchanged (Table 1).4.1. Ang-2 loss-of-function model contradictory to gain-of-function
model in atherosclerosis
To date, inhibition or knock-out of endogenous Ang-2 in human
or murine atherosclerosis have not been reported. However, Ang-2
overexpression was shown to decrease plaque formation in the
aortic root of ApoE knock-out mice via inhibition of LDL oxidation
[6]. However, the impact on plaque stability was not studied in
great detail. The authors only observed an absolute decrease in
plaque macrophages after Ang-2 overexpression, albeit that data
were not corrected for the reduced overall plaque size [6]. There-
fore, the reduction in macrophage area probably only reﬂects the
plaque stage. Concordant with this notion, in our study, we did not
observe any difference in relative macrophage content (macro-
phage area normalized to the plaque area) after Ang-2 blockage.
Fig. 4. Advanced lesions in the carotid arteries are not affected by Ang-2 blockage.
Representative images of HE-stained collar induced advanced plaques (A þ B) in the
right common carotid artery. Plaque size (C) necrotic core (D). Representative images
and quantiﬁcation of (EeG) collagen, (HeJ) macrophages, (KeM) microvessels: left
control IgG, right anti-Ang-2. IgG n ¼ 12; anti-Ang-2 n ¼ 14.
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However, transgenic Ang-2 overexpression does not mimic the
endogenous role of Ang-2 in atherogenesis, which is crucial for the
translation to the human situation.4.2. No role for Ang-2 blockage in plaque stabilization
Considering the stimulatory role of Ang-2 in various processes
associated with vulnerable plaques [18], such as increased inﬂam-
mation [13], plaque vascularity [5], microvascular leakage [15] and
MMP expression [5], we expected profound effects of Ang-2
antagonism on the stable plaque phenotype. However, Ang-2
deletion was only able to prevent fatty streak formation; it did
not prevent plaque progression or changes in plaque stability.Table 1
Summarizing table of the described data.
Parameter Tissue
Plaque burden Plaque size Brachioce
Collar mo
Aortic roo
Degree of stenosis Brachioce
Plaque phenotype Necrotic core Brachioce
Collar mo
Aortic roo
Plaque collagen Brachioce
Aortic roo
Plaque macrophages Brachioce
Aortic roo
Microvessel density Brachioce
Aortic roo
Systemic effects Angiopoetin-2 Plasma
Cholesterol Plasma
Triglycerides Plasma
Cardiac function US of the
Carotid strain þ shear stress US of caro
Body weight Before sac
US ¼ ultra sound; n.s. ¼ not signiﬁcant.
*p < 0.05, **p < 0.01.Changes in fatty streak formation could not be attributed to
effects on plaque inﬂammation or angiogenesis. Rather, Ang-2
blockage may retard fatty streak formation by a reduction in
plasma triglycerides, prevention of endothelial dysfunction or
reduction of monocyte chemotaxis. We observed lower plasma
triglycerides after Ang-2 antibody treatment, which might explain
the decrease in fatty streak formation. Until recently, hyper-
triglyceridemia was regarded as a risk factor of cardiovascular
disease based on epidemiological association only, with much
controversy on possible causality. However, recent Mendelian
randomization studies increasingly support the causative role for
increased plasma triglycerides in cardiovascular disease and
atherosclerosis [29,30]. Cellular effects are mediated by remnant
lipoproteins, rich in triglycerides, rather than chylomicrons
(reviewed in [31]). Mechanistically, direct uptake of these remnant
lipoproteins by macrophages stimulates cholesterol ester accu-
mulation and macrophage foam cell formation, an important step
in fatty streak formation [32]. Neutral and oxidized free fatty acids
generated by lipolysis of these triglyceride-rich lipoproteins can
also stimulate endothelial dysfunction, subsequently enhancing
vascular inﬂammation and lipoprotein retention [33], and hence
fatty streak formation [31]. Thus, lower triglycerides may prevent
endothelial dysfunction and foam cell formation, explaining the
reduction in fatty streak formation. Although high triglyceride
levels have also been associated with clinically relevant athero-
sclerosis [34], reduced levels were without effect on pre-existing
atherosclerosis in our model.
Ang-2 blockage could decrease fatty streak formation also via
processes that are regulated by the angiopoietin receptor Tie2,
which is highly expressed in endothelial cells and monocytes, both
involved in the early development of atherosclerosis. Ang-2
expressed by endothelial cells has been shown to stimulate
monocyte chemotaxis [35], hence Ang-2 blockage may reduce
monocyte recruitment to developing fatty streaks. However, as we
did not observe alterations in macrophage content of fatty streaks,
this seems unlikely. More likely, is the involvement of endothelial
cell dysfunction and the subsequent permeability for lipoproteins.
This is thought to be the initial step at the onset of atherosclerosis.
Ang-2 is known to induce endothelial destabilization and vascular
permeability [36], thus suggesting a beneﬁcial effect of Ang-2
blockage.Alteration in anti-Ang-2 mice Statistics
phalic artery Y *
del ¼ n.s.
t ¼ n.s.
phalic artery Y **
phalic artery Absent in fatty streak e
del ¼ n.s.
t ¼ n.s.
phalic artery ¼ n.s.
t ¼ n.s.
phalic artery ¼ n.s.
t ¼ n.s.
phalic artery ¼ n.s.
t ¼ n.s.
[ **
¼ n.s.
Y *
heart ¼ n.s.
tid artery ¼ n.s.
riﬁce ¼ n.s.
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models
The Ang-2 blocking capacity of anti-Ang2 antibodies in vitro
[12] and in vivo [12,22,27,37] has been ﬁrmly established and was
conﬁrmed in our study by using Ang-2 ELISA. It has been reported
that treatment of cardiac allografts with anti-Ang2 protects from
transplant inﬂammation and rejection [37]. This is in line with
atherosclerosis inhibition by overexpression of the Tie2 agonist
ligand, Ang1 in cardiac allografts [38]. Antibody-mediated Ang-2
blockage has been proven to reduce tumor growth [12] and lung
metastasis formation [22] in murine cancer models by increasing
tumor vessel stability. Moreover, Ang-2 is released by endothelial
cells [39], thus anti-Ang-2 antibody has perfect access to the target
through the adventitial microvasculature and themain arteries. It is
thus unlikely that Ang-2 depletion or impaired tissue availability of
the antibody could explain the lack of effect on plaque progression
and stable plaque phenotype.4.4. Inhibiting Ang-2 alone might not be sufﬁcient
Alternatively, inhibiting Ang-2 only might not sufﬁce to affect
pre-existing atherosclerosis. Additional factors, such as vascular
endothelial growth factor A (VEGF-A) should be targeted as well.
For example, one could employ a bifunctional anti-VEGF-A/anti-
Ang-2 antibody, which combines the inhibition of both growth
factors; this has already provided a stronger anti-tumor effect than
targeting the two growth-factors separately [40].4.5. Ang-2 cause or consequence of atherosclerosis
The lack of effect on plaque growth or the stable plaque
phenotype is in contrast to previously reported associations be-
tween Ang-2 and cardiovascular disease. Increased Ang-2 plasma
levels have been correlated with cardiovascular disease progres-
sion, but have also been suggested to provide a biomarker for future
cardiovascular events such as myocardial infarction or stroke
[3,41e47]. Furthermore, Ang-2 was detected in advanced vascu-
larized human plaques [48] and it was associated with a high
microvessel content and destabilizing MMP-2 expression [5]. The
outcomes of these studies support our ﬁndings that Ang-2 deple-
tion helps to inhibit atherosclerosis development. Nevertheless, not
all studies could show a correlation of Ang-2 with plaques at risk of
rupture [49,50]. Perhaps the clinical correlation of Ang-2 expres-
sion and atherosclerosis reﬂects a compensatory expression in
response to plaque vulnerability. Overall, Ang-2 may be correlated
with cardiovascular diseases, but the results described in the pre-
sent work do not support a causal role for it in atherosclerosis
progression or plaque vulnerability. Importantly, our study gives no
reason to think that Ang-2 blockage could have adverse effects on
pre-existing atherosclerosis of treated cancer patients.5. Conclusions
This is the ﬁrst time Ang-2 blockage has been tested in an
experimental model of atherosclerosis and found to have signiﬁ-
cant protective effects on fatty streak formation. Ang-2 blockage
reduces plasma triglycerides and decreases early plaque formation,
suggesting a beneﬁcial effect of Ang-2 depletion on the early phase
of atherosclerosis. In addition, no effects on pre-existing athero-
sclerosis or cardiac functionwere found, suggesting that anti-Ang-2
therapy is safe in various clinical settings.6. Signiﬁcance in the context of atherosclerosis
The present study is the ﬁrst to investigate the effect of blocking
Ang-2 on experimental atherosclerosis. In addition, the cardiovas-
cular safety of the Ang-2 blocking was studied. It was shown that
anti-Ang-2 therapy delayed fatty streak formation and decreased
plasma triglyceride levels. Pre-existing atherosclerosis and cardiac
function were unaltered. The results suggest a favorable safety
proﬁle for the clinical use of antibody mediated Ang-2 blockage.
Sources of funding
Research was supported by Finnish Academy (141069), ERC
(ERC-2009-AdG-250050, FutureGenes) grant, Sigrid Juselius Foun-
dation, Finnish Foundation for Cardiovascular Research (all to S.Y.);
the European Research Council (ERC-2010-AdG-268804, VESSEL
network), Leducq Transatlantic Network of Excellence on Lymph
Vessels in Obesity and Cardiovascular Disease (11CVD03) (all to
K.A.), a VENI fellowship of the Netherlands Organization of Scien-
tiﬁc research (to J.C.S. 016.116.017); a PhD-student fellowship from
the Cardiovascular Research Institute Maastricht (to T.L.T.).
Disclosures
None.
Acknowledgements
The authors would like to thank Dr. ChingChing Leow and
MedImmune for the anti-Ang-2 antibodies, and the staff of the
Experimental animal facility at the University of Eastern Finland,
Kuopio.
References
[1] J.M. Llovet, et al., Plasma biomarkers as predictors of outcome in patients with
advanced hepatocellular carcinoma, Clin. Cancer Res. 18 (2012) 2290e2300.
[2] T. Ziegler, et al., Angiopoietin 2 mediates microvascular and hemodynamic
alterations in sepsis, J. Clin. Invest. 123 (8) (2013) 3436e3445.
[3] C. Iribarren, et al., Circulating angiopoietins-1 and -2, angiopoietin receptor
tie-2 and vascular endothelial growth factor-a as biomarkers of acute
myocardial infarction: a prospective nested case-control study, BMC Car-
diovasc. Disord. 11 (2011) 31.
[4] J. Le Dall, et al., Immaturity of microvessels in haemorrhagic plaques is
associated with proteolytic degradation of angiogenic factors, Cardiovasc. Res.
85 (2010) 184e193.
[5] S. Post, et al., Balance between angiopoietin-1 and angiopoietin-2 is in favor of
angiopoietin-2 in atherosclerotic plaques with high microvessel density,
J. Vasc. Res. 45 (2008) 244e250.
[6] A. Ahmed, et al., Angiopoietin-2 confers atheroprotection in apoe-/- mice by
inhibiting ldl oxidation via nitric oxide, Circ. Res. 104 (2009) 1333e1336.
[7] E.J. Bowles, et al., Risk of heart failure in breast cancer patients after anthra-
cycline and trastuzumab treatment: a retrospective cohort study, J. Natl.
Cancer Inst. 104 (2012) 1293e1305.
[8] J. Chen, et al., Incidence of heart failure or cardiomyopathy after adjuvant
trastuzumab therapy for breast cancer, J. Am. Coll. Cardiol. 60 (2012)
2504e2512.
[9] T.K. Choueiri, et al., Congestive heart failure risk in patients with breast cancer
treated with bevacizumab, J. Clin. Oncol. 29 (2011) 632e638.
[10] F.A. Scappaticci, et al., Arterial thromboembolic events in patients with met-
astatic carcinoma treated with chemotherapy and bevacizumab, J. Natl. Can-
cer Inst. 99 (2007) 1232e1239.
[11] P. Saharinen, et al., Vegf and angiopoietin signaling in tumor angiogenesis and
metastasis, Trends Mol. Med. 17 (2011) 347e362.
[12] C.C. Leow, et al., Medi3617, a human anti-angiopoietin 2 monoclonal anti-
body, inhibits angiogenesis and tumor growth in human tumor xenograft
models, Int. J. Oncol. 40 (2012) 1321e1330.
[13] U. Fiedler, et al., Angiopoietin-2 sensitizes endothelial cells to tnf-alpha and
has a crucial role in the induction of inﬂammation, Nat. Med. 12 (2006)
235e239.
[14] I.B. Lobov, et al., Angiopoietin-2 displays vegf-dependent modulation of
capillary structure and endothelial cell survival in vivo, Proc. Natl. Acad. Sci. U.
S. A. 99 (2002) 11205e11210.
[15] A.V. Benest, et al., Angiopoietin-2 is critical for cytokine-induced vascular
T.L. Theelen et al. / Atherosclerosis 241 (2015) 297e304304leakage, PLoS One 8 (2013) e70459.
[16] V. Bhandari, et al., Hyperoxia causes angiopoietin 2-mediated acute lung
injury and necrotic cell death, Nat. Med. 12 (2006) 1286e1293.
[17] C. Murdoch, et al., Expression of tie-2 by human monocytes and their re-
sponses to angiopoietin-2, J. Immunol. 178 (2007) 7405e7411.
[18] S. Yla-Herttuala, et al., Stabilization of atherosclerotic plaques: an update, Eur.
Heart J. 34 (2013) 3251e3258.
[19] P.R. Moreno, et al., Plaque neovascularization is increased in ruptured
atherosclerotic lesions of human aorta: implications for plaque vulnerability,
Circulation 110 (2004) 2032e2038.
[20] J.C. Sluimer, et al., Thin-walled microvessels in human coronary atheroscle-
rotic plaques show incomplete endothelial junctions relevance of compro-
mised structural integrity for intraplaque microvascular leakage, J. Am. Coll.
Cardiol. 53 (2009) 1517e1527.
[21] J.H. von der Thusen, et al., Induction of rapid atherogenesis by perivascular
carotid collar placement in apolipoprotein e-deﬁcient and low-density lipo-
protein receptor-deﬁcient mice, Circulation 103 (2001) 1164e1170.
[22] T. Holopainen, et al., Effects of angiopoietin-2-blocking antibody on endo-
thelial cell-cell junctions and lung metastasis, J. Natl. Cancer Inst. 104 (2012)
461e475.
[23] J. Huusko, et al., Aav9-mediated vegf-b gene transfer improves systolic
function in progressive left ventricular hypertrophy, Mol. Ther. 20 (2012)
2212e2221.
[24] A. Feintuch, et al., Hemodynamics in the mouse aortic arch as assessed by mri,
ultrasound, and numerical modeling, Am. J. Physiol. Heart Circ. Physiol. 292
(2007) H884eH892.
[25] Y. Castier, et al., P47phox-dependent nadph oxidase regulates ﬂow-induced
vascular remodeling, Circ. Res. 97 (2005) 533e540.
[26] E. Lutgens, et al., Atherosclerosis in apoe*3-leiden transgenic mice: from
proliferative to atheromatous stage, Circulation 99 (1999) 276e283.
[27] R.B. Natale, et al., Safety, pharmacokinetics, and antitumor activity of
medi3617, a selective angiopoietin inhibitor, in adult patients with advanced
solid tumors, J. Clin. Oncol. 30 (2012) (suppl; abstr TPS2621).
[28] E. Lutgens, et al., Requirement for cd154 in the progression of atherosclerosis,
Nat. Med. 5 (1999) 1313e1316.
[29] C.T. Johansen, et al., Using mendelian randomization to determine causative
factors in cardiovascular disease, J. Intern Med. 273 (2013) 44e47.
[30] A.B. Jorgensen, et al., Genetically elevated non-fasting triglycerides and
calculated remnant cholesterol as causal risk factors for myocardial infarction,
Eur. Heart J. 34 (2013) 1826e1833.
[31] G.F. Watts, et al., Demystifying the management of hypertriglyceridaemia,
Nat. Rev. Cardiol. 10 (2013) 648e661.
[32] J.L. Goldstein, et al., Cholesteryl ester accumulation in macrophages resulting
from receptor-mediated uptake and degradation of hypercholesterolemic
canine beta-very low density lipoproteins, J. Biol. Chem. 255 (1980)
1839e1848.
[33] L. Wang, et al., Triglyceride-rich lipoprotein lipolysis releases neutral andoxidized ffas that induce endothelial cell inﬂammation, J. Lipid Res. 50 (2009)
204e213.
[34] Triglyceride Coronary Disease Genetics C, et al., Triglyceride-mediated path-
ways and coronary disease: collaborative analysis of 101 studies, Lancet 375
(2010) 1634e1639.
[35] A. Scholz, et al., Angiopoietin-2 promotes myeloid cell inﬁltration in a beta(2)-
integrin-dependent manner, Blood 118 (2011) 5050e5059.
[36] L. Hakanpaa, et al., Endothelial destabilization by angiopoietin-2 via integrin
beta1 activation, Nat. Commun. 6 (2015) 5962.
[37] S.O. Syrjala, et al., Angiopoietin-2 inhibition prevents transplant ischemia-
reperfusion injury and chronic rejection in rat cardiac allografts, Am. J.
Transpl. 14 (2014) 1096e1108.
[38] A.I. Nykanen, et al., Angiopoietin-1 protects against the development of car-
diac allograft arteriosclerosis, Circulation 107 (2003) 1308e1314.
[39] H.G. Augustin, et al., Control of vascular morphogenesis and homeostasis
through the angiopoietin-tie system, Nat. Rev. Mol. Cell Biol. 10 (2009)
165e177.
[40] Y. Kienast, et al., Ang-2-vegf-a crossmab, a novel bispeciﬁc human igg1
antibody blocking vegf-a and ang-2 functions simultaneously, mediates
potent antitumor, antiangiogenic, and antimetastatic efﬁcacy, Clin. Cancer
Res. 19 (2013) 6730e6740.
[41] N.A. Chung, et al., Measurement of the soluble angiopoietin receptor tie-2 in
patients with coronary artery disease: development and application of an
immunoassay, Eur. J. Clin. Invest. 33 (2003) 529e535.
[42] S. David, et al., Angiopoietin 2 and cardiovascular disease in dialysis and
kidney transplantation, Am. J. Kidney Dis. 53 (2009) 770e778.
[43] S. David, et al., Circulating angiopoietin-2 in essential hypertension: relation
to atherosclerosis, vascular inﬂammation, and treatment with olmesartan/
pravastatin, J. Hypertens. 27 (2009) 1641e1647.
[44] J. Golledge, et al., Increased serum angiopoietin-2 is associated with abdom-
inal aortic aneurysm prevalence and cardiovascular mortality in older men,
Int. J. Cardiol. 167 (2013) 1159e1163.
[45] K.W. Lee, et al., Plasma angiopoietin-1, angiopoietin-2, angiopoietin receptor
tie-2, and vascular endothelial growth factor levels in acute coronary syn-
dromes, Circulation 110 (2004) 2355e2360.
[46] J.V. Patel, et al., Angiopoietin-2 levels as a biomarker of cardiovascular risk in
patients with hypertension, Ann. Med. 40 (2008) 215e222.
[47] X. Wang, et al., Changes and signiﬁcance of serum angiopoietin-2 levels in
patients with coronary heart disease, Biomarkers 17 (2012) 745e749.
[48] C. Calvi, et al., Angiopoietin 2 induces cell cycle arrest in endothelial cells: a
possible mechanism involved in advanced plaque neovascularization, Arte-
rioscler. Thromb. Vasc. Biol. 24 (2004) 511e518.
[49] F. Chen, et al., Apoptosis and angiogenesis are induced in the unstable coro-
nary atherosclerotic plaque, Coron. Artery Dis. 16 (2005) 191e197.
[50] J. Pelisek, et al., Neovascularization and angiogenic factors in advanced human
carotid artery stenosis, Circ. J. 76 (2012) 1274e1282.
